搜尋
EyePoint Pharmaceuticals Inc
EYPT添加自選
13.980USD
+0.785+5.95%
收盤 07/02, 13:00（美東）報價延遲15分鐘
1.16B總市值
虧損本益比TTM
關於 EyePoint Pharmaceuticals Inc 公司
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Company’s other products include YUTIQ and DEXYCU.
EyePoint Pharmaceuticals Inc簡介
公司代碼EYPT
公司名稱EyePoint Pharmaceuticals Inc
上市日期Jan 27, 2005
CEODuker (Jay S)
員工數量165
證券類型Ordinary Share
年結日Jan 27
公司地址480 Pleasant Street, Suite C400
城市WATERTOWN
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編02472
電話16179265000
網址https://eyepointpharma.com/
公司代碼EYPT
上市日期Jan 27, 2005
CEODuker (Jay S)
EyePoint Pharmaceuticals Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
944.09K
+28.33%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Executive Vice Chairman of the Board
Executive Vice Chairman of the Board
649.85K
-0.52%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
182.86K
+21.87%
Ms. Karen L. Zaderej
Ms. Karen L. Zaderej
Non-Executive Independent Director
Non-Executive Independent Director
164.61K
+28.75%
Mr. Stuart Duty
Mr. Stuart Duty
Non-Executive Independent Director
Non-Executive Independent Director
105.01K
+57.14%
Mr. Ramiro Ribeiro, M.D., Ph.D.
Mr. Ramiro Ribeiro, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
75.19K
+48.05%
Mr. Fred Hassan
Mr. Fred Hassan
Non-Executive Independent Director
Non-Executive Independent Director
60.00K
--
Dr. Goeran A. Ando, M.D.
Dr. Goeran A. Ando, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Wendy F. Dicicco, CPA
Ms. Wendy F. Dicicco, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. George Elston
Mr. George Elston
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
944.09K
+28.33%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Executive Vice Chairman of the Board
Executive Vice Chairman of the Board
649.85K
-0.52%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
182.86K
+21.87%
Ms. Karen L. Zaderej
Ms. Karen L. Zaderej
Non-Executive Independent Director
Non-Executive Independent Director
164.61K
+28.75%
Mr. Stuart Duty
Mr. Stuart Duty
Non-Executive Independent Director
Non-Executive Independent Director
105.01K
+57.14%
Mr. Ramiro Ribeiro, M.D., Ph.D.
Mr. Ramiro Ribeiro, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
75.19K
+48.05%
常見問題
EyePoint Pharmaceuticals Inc的前五大股東是誰？
EyePoint Pharmaceuticals Inc的前五大股東如下：Dr. Jay S. Duker, M.D.
有多少機構持有EyePoint Pharmaceuticals Inc(EYPT)的股份？
截至2026Q1，共有381家機構持有EyePoint Pharmaceuticals Inc的股份，合計持有的股份價值約為88.53M，占公司總股份的105.59% 。與2025Q4相比，機構持股有所增加，增幅為-2754490.00。
哪個業務部門對EyePoint Pharmaceuticals Inc的收入貢獻最大？
在2026Q1，YUTIQ業務部門對EyePoint Pharmaceuticals Inc的收入貢獻最大，創收1.60M，占總收入的5.10% 。